Toward a Single-Dose Cure for Buruli Ulcer.

Thomas, Sangeeta S; Kalia, Nitin Pal; Ruf, Marie-Thérèse; Pluschke, Gerd; Pethe, Kevin

Thomas, Sangeeta S; Kalia, Nitin Pal; Ruf, Marie-Thérèse; Pluschke, Gerd; Pethe, Kevin.

Afiliação

Thomas SS; NTU Institute for Health Technologies (HealthTech NTU), Interdisciplinary Graduate Programme, Nanyang Technological University, Singapore.
Kalia NP; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
Ruf MT; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
Pluschke G; Clinical Microbiology Division, CSIR-IIIM, Jammu and Kashmir, India.
Pethe K; Swiss Tropical and Public Health Institute, Basel, Switzerland.

Antimicrob Agents Chemother ; 64(9)2020 08 20.

Article em En | MEDLINE | ID: mdl-32631818

ABSTRACT

ABSTRACT

A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.

Assuntos

Úlcera de Buruli; Mycobacterium ulcerans; Tuberculose; Animais; Úlcera de Buruli/tratamento farmacológico; Modelos Animais de Doenças; Camundongos

Palavras-chave

Mycobacterium ulcerans; Q203; Telacebec; bedaquiline; bioenergetics; cytochrome bcc-aa3; oxidative phosphorylation; terminal oxidase; tuberculosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Mycobacterium ulcerans / Úlcera de Buruli Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google